# 2025-16274: PIASKY Gets FDA Nod for Longer Patent Lifespan Extension

2025-16274, Determination of Regulatory Review Period for Purposes of Patent Extension; PIASKY, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-26 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-16274
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-16274
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; PIASKY
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 41576
- Published: 2025-08-26
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

PIASKY Gets FDA Nod for Longer Patent Lifespan Extension

## Summary

The FDA has officially set the review period for PIASKY, a human biological product, so its patent can be extended. This helps the company get extra time to protect their invention after going through the approval process. If you’re involved in biotech or patents, this means the clock is ticking on PIASKY’s exclusive rights and potential market impact.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PIASKY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-16274 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/26/2025-16274/determination-of-regulatory-review-period-for-purposes-of-patent-extension-piasky)
- [2025-16274 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-26/pdf/2025-16274.pdf)

## Related
- [Previous: 2025-16273, Determination of Regulatory Review Period for Purposes of Patent Extension; CAM…](https://policyrisk.com/federal-register/2025-16273)
- [Next: 2025-16275, Determination of Regulatory Review Period for Purposes of Patent Extension; SOF…](https://policyrisk.com/federal-register/2025-16275)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-16274 (as of 2026-06-08).
